Delving into the Latest Updates on Levobupivacaine Hydrochloride with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

(-)-bupivacaine, (S)-1-butyl-2',6'-pipecoloxylidide, (S)-bupivacaine

+ [17]

Target

SCNA

Action

blockers

Mechanism

SCNA blockers(Sodium channel alpha subunit blockers)

Therapeutic Areas

Nervous System DiseasesOther Diseases

Active Indication

AnesthesiaPain

Inactive Indication-

Originator Organization

Purdue Pharma LP

Active Organization

AbbVie Pty Ltd.

Jiangsu Hengrui Pharmaceuticals Co., Ltd.

Maruishi Pharmaceutical Co., Ltd.

Inactive Organization

Purdue Pharma LP

Drug Highest PhaseApproved

First Approval Date

United States (05 Aug 1999),

AnesthesiaPain

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC18H29ClN2O

InChIKeySIEYLFHKZGLBNX-NTISSMGPSA-N

CAS Registry27262-48-2

View All Structures (2)

BACKGROUNDPostoperative pain following spine surgery remains a challenge for patients, surgeons and healthcare facilities. This study aimed to evaluate the postoperative analgesic efficacy of gelfoam soaked in pethidine combined with levobupivacaine, compared to gelfoam soaked in levobupivacaine alone in single-level lumbar laminectomy patients.METHODSThis was a prospective, randomized, double blinded study. A total of 90 patients of either sex, aged 18 to 60 years with ASA class I or II planned for single-level lumbar laminectomy were randomly assigned into three equal groups: group A (levobupivacaine plus pethidine): epidural gelfoam soaked with 1 ml levobupivacaine 0.25 % plus 1 ml pethidine 50 mg, group B (levobupivacaine alone): epidural gelfoam soaked with 1 ml levobupivacaine 0.25 % plus 1 ml of 0.9 % sodium chloride; and group C (control group): epidural gelfoam soaked with 2 ml of 0.9 % sodium chloride. Total analgesic consumption, time to first rescue analgesic request, time to ambulate, postoperative VAS scores, vital signs and adverse effects were recorded.RESULTSDemographic and baseline patients' data were comparable among the 3 groups. Group B had lower total analgesic consumption, prolonged time to first rescue analgesia, earlier ambulation, and lower VAS scores in the first 24 h in compared to control group C. Significant differences were found between groups A and B in total analgesic consumption, time to first rescue analgesia, and VAS score in the first 24 h. However, no significant differences were found between the two groups regarding time of ambulation and average VAS scores 24 to 48 h after surgery. There were no significant differences in the occurrence of adverse effects among the 3 groups.CONCLUSIONSThis study demonstrated that the addition of pethidine to epidural levobupivacaine in a gelfoam soaked form enhanced the postoperative analgesia in patients undergoing single-level lumbar laminectomy in terms of reduced total analgesic consumption, prolonged time to first rescue analgesia and lower postoperative pain scores.

01 Feb 2025·American Journal of Physiology-Endocrinology and Metabolism

Method for measuring cervical vagal nerve activity in conscious rats

Article

Author: Ikegame, Shizuka ; Miyaura, Wakana ; Miki, Kenju ; Yoshimoto, Misa

This study proposed a method for directly measuring cervical vagal nerve activity and reversibly blocking afferent cVNA in conscious rats. It demonstrated that CCK-8, when administered intraperitoneally, distinctly influences peripheral afferent vagal nerve activity without affecting renal sympathetic nerve activity, arterial pressure, or heart rate.

03 Jan 2025·Cureus

A Double-Blind Randomized Controlled Trial Comparing Intrathecal 0.5% Isobaric Levobupivacaine With Fentanyl to 0.5% Isobaric Ropivacaine With Fentanyl for Elective Cesarean Section

Article

Author: Deganwa, Mangilal ; Juneja, Disha ; Verma, Kalpana ; Singh, Sapna

Background This study was planned to compare the onset and duration of action and the levels of sensory and motor blocks of 0.5% isobaric levobupivacaine with fentanyl to 0.5% isobaric ropivacaine with fentanyl addition in subarachnoid block in elective cesarean cases. Materials and methods This hospital-based randomized interventional controlled study was conducted in a tertiary care facility in Jaipur. Sixty women who planned for elective lower-segment cesarean section, with more than 37 weeks of gestational period during the study period, were included in our study. These women were randomly divided into two study groups, using sealed opaque envelopes, and double blinding was ensured. In group L, women received 0.5% isobaric levobupivacaine with fentanyl, and in group R, 0.5% isobaric ropivacaine with fentanyl was given. Results The mean time for sensory and motor block onset was significantly lower in group L than in group R (p<0.05). The mean time for two-segment regression for sensory block was significantly higher in group L than in group R (p<0.05). The mean duration of total motor blockade (B0) was significantly higher in group L compared to group R. The differences in the mean duration of total motor blockade were statistically significant (p<0.05). The mean change in mean arterial pressure (MAP) in group L was significantly higher than in group R (p<0.05). Conclusion This study provides valuable insights into the comparative effects of 0.5% isobaric levobupivacaine with fentanyl and 0.5% isobaric ropivacaine with fentanyl for spinal anesthesia in cesarean sections. Both anesthetic agents were well-tolerated, with no severe complications or side effects observed in either group. While levobupivacaine offers an early onset of action, ropivacaine demonstrates a more favorable hemodynamic profile with an early regression of motor block. Ropivacaine may be a suitable alternative to levobupivacaine for spinal anesthesia in cesarean sections, particularly in patients with unstable hemodynamics. Further research is necessary to investigate the long-term effects of these agents and to optimize their use in different patient populations.

2

News (Medical) associated with Levobupivacaine Hydrochloride

07 Nov 2023

·www.prnewswire.com

Advanced Anesthesia Devices and Ambulatory Surgical Centers Propel Growth in the US Anesthesia Market

DUBLIN, Nov. 7, 2023 /PRNewswire/ -- The "The US Anesthesia Drugs and Devices Market (by segment, Type, Drug Product, & Device Product): Insights and Forecast with Potential Impact of COVID-19 (2022-2027)" report has been added to ResearchAndMarkets.com's offering. The US anesthesia drugs and devices market is poised for significant growth, with a projected value of US$6.83 billion in 2023, experiencing a robust CAGR of 6.78% during the forecasted period. Anesthesia, the use of drugs to alleviate pain during medical procedures, is essential in the healthcare industry and is administered through various means such as injection, inhalation, topical application, and more. Market Segmentation The US anesthesia drugs and devices market is divided into two primary segments: anesthesia drugs and anesthesia devices. Among these segments, anesthesia drugs currently hold the majority share, while the anesthesia devices segment is expected to experience substantial growth due to increased healthcare expenditure in the region. Types and Products In terms of types, the US anesthesia drugs market is categorized into General, Local, and other anesthesia. The General anesthesia drug segment dominates the market, followed by local anesthesia drugs. The development of novel anesthesia drugs through pharmaceutical R&D is expected to create growth opportunities in the "other anesthesia drugs" segment. When considering device products, the market is segmented into advanced, basic, and integrated anesthesia devices. The advanced segment holds the largest share in the market, followed by integrated anesthesia devices. Ongoing advancements in anesthesia monitoring devices and the demand for improved monitoring contribute to the growth of the advanced anesthesia monitoring devices market. The market is further categorized by drug product into Bupivacaine, Ropivacaine, Lidocaine, Chloroprocaine, Prilocaine, Benzocaine, and other local anesthetics. Lidocaine anesthesia drugs have the highest market share, followed by Bupivacaine and Ropivacaine. The market is anticipated to grow due to increasing patient populations and a rise in medical and surgical procedures. Key Drivers and Challenges Driver: Increase in Monitored Anesthesia Use The adoption of Monitored Anesthesia Care (MAC) is on the rise. MAC involves specific anesthesia services for procedures performed under local anesthesia with sedation and analgesia, allowing patients to maintain consciousness. Patients are opting for monitored anesthesia to ensure satisfaction during surgeries, leading to increased usage of anesthesia equipment and drugs. Challenge: Side Effects of Anesthesia While anesthesia is generally administered by anesthesiologists, it can sometimes lead to side effects, including nausea, headache, vomiting, and shivering, among others. General anesthetics can affect the central nervous system, causing drowsiness and coordination problems. These side effects can deter some patients and impact the growth of the anesthesiology market. Trend: Growth of Ambulatory Surgical Centers (ASC) The establishment of ambulatory surgical centers (ASCs) is escalating due to an aging population and the prevalence of chronic diseases. ASCs offer improved reimbursement and a reduced risk of healthcare-associated infections, attracting more patients. This growth in ASCs is driving the demand for anesthesia drugs and devices. COVID-19 Analysis The COVID-19 pandemic led to increased utilization of intensive care unit (ICU) ventilators and anesthesia machines for longer-term ventilation. Anesthesia drugs were used during longer-term ventilation with anesthesia machines. Initially, anesthesia drug demand decreased in 2020 due to postponed or canceled surgeries. However, as elective surgeries resumed, anesthesia drug consumption increased. Key Players The US anesthesia drugs and devices market is competitive and features several major players, including Baxter International Inc., Envision Healthcare Corporation (KKR & Co. Inc.), Becton, Dickinson and Company, TeamHealth (Blackstone), Teleflex Incorporated, Dragerwerk AG & Co. KGaA, B. Braun Avitum AG (Braun), 3M Company, Abbvie Inc., AstraZeneca Plc, Abbott Laboratories, ICU Medical, Inc., SunMed LLC, and General Electric Company. Top Impacting Factors Growth Drivers Rising Geriatric Population Growing Healthcare Expenditure Increase in Monitored Anesthesia Use Increase In Number Of Approval For Anesthesia Drugs Challenges Side Effects of Anesthesia Lack of Skilled Anesthesiologist Trends Escalating Establishment of Ambulatory Surgical Centers (ASC) Technological Enhancement of Anesthesia Devices For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo - SOURCE Research and Markets

18 Nov 2022

·www.prnewswire.com

US Anesthesia Drugs and Devices Market to Reach $8.88 Billion by 2027

DUBLIN, Nov. 18, 2022 /PRNewswire/ -- The "The US Anesthesia Drugs and Devices Market: Analysis By segment, By Type, By Drug product, By Device Product, Size And Trends With Impact of COVID-19 and Forecast up to 2027" report has been added to ResearchAndMarkets.com's offering. The US anesthesia drugs and devices market in 2021 was valued at US$5.99 billion. The market value is predicted to reach US$8.88 billion by 2027. Anesthesia is the use of medicines to prevent pain during surgery and other procedures. They may be given by injection, inhalation, topical lotion, spray, eye drops, or skin patch. Anesthesia can cause one to have a loss of feeling or awareness. The market is expected to grow at a CAGR of 6.80% during the forecast period of 2022-2027. Due to increasing number of surgeries, aging population with increasing chronic conditions, and advancements in anesthesia technologies, the market for anesthesia drugs and devices would grow in the years to come. Market Segmentation Analysis: By Segment: The report provides the bifurcation of the market into two categories based on the segment: anesthesia drugs and anesthesia devices. In 2021, anesthesia drugs segment held a major share of more than 55% in the market. On the other hand, the anesthesia devices segment is expected to grow at a significant CAGR in the forthcoming years owing to the rising healthcare expenditure in the region. By Type: On the basis of type, the US anesthesia drugs market is divided into three types namely general, local and other anesthesia. In 2021, general anesthesia drug segment held a major share of more than 39% in the market. This was being followed by local anesthesia drugs. R&D activities in the pharmaceutical industry to formulate novel anesthesia drug is expected to provide remunerative opportunities for expansion of the US other anesthesia drugs market during forecast period. By Device Product: The report provides the bifurcation of the market into three segments based on the device product: advanced, basic and integrated. In 2021, advanced segment held a major share of 62% in the market. This was being followed by integrated anesthesia device. The constant development in the field of the anesthesia monitoring devices and high demand for the better monitoring devices are also anticipated to push the growth in the US advanced anesthesia monitoring devices market. By Drug Product: The report provides the bifurcation of the market into seven segments based on the drug product: Bupivacaine, Ropivacaine, Lidocaine, Chloroprocaine, Prilocaine, Benzocaine and Other Local Anesthetics. In 2021, Lidocaine anesthesia drug segment held a major share of 32% in the market. This was being followed by Bupivacaine, Ropivacaine. The market is anticipated to propel during forecasted years owing to the expanding patient population and the rise in medical and surgical procedures. Market Dynamics: Growth Drivers: One of the most important factors impacting the US anesthesia drugs and devices market is rising geriatric population. Steady growth in aging population raised the incidence of the chronic condition over the past decade. This had caused increasing number of surgical procedures of elderly patients. Additionally, benefits such as advances in surgery and anesthesia can improve function and quality of life for older patients also supported market growth. Thus, the positive acceleration in aging population consequently supported the growth of the anesthesia drugs and devices market in the US. Furthermore, the market has been growing over the past few years, due to factors such as growing healthcare expenditure, increase in monitored anesthesia use, increase in number of approval for anesthesia drugs and many other factors. Challenges: However, the market has been confronted with some challenges specifically, lack of skilled anesthesiologist, etc. - Trends: The market is projected to grow at a fast pace during the forecast period, due to various latest trends such as the escalating establishment of ambulatory surgical centers (ASC), technological enhancement of anesthesia devices, etc. Technology upgradation such as Closed loop TIVA and Ultrasound-Guided Regional Anesthesia (UGRA) are expected to propel the US drug and devices market during forecasted years. Key Topics Covered: 1. Executive Summary 2. Introduction 3. Market Analysis 4. Impact of COVID-19 5. Market Dynamics 6. Competitive Landscape 7. Company Profiles Companies Mentioned KKR & Co. Inc. (Envision Healthcare Corporation) Baxter International Inc. Blackstone (TeamHealth) Becton, Dickinson and Company Braun (B. Braun Avitum AG) 3M Company Abbvie Inc. Teleflex Incorporated Dragerwerk AG & Co. KGaA AstraZeneca Plc Abbott Laboratories General Electric Company ICU Medical, Inc SunMed LLC For more information about this report visit Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

100 Deals associated with Levobupivacaine Hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D01287	Levobupivacaine Hydrochloride	N01BB10	DB01002

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Anesthesia	Australia	AbbVie Pty Ltd.	07 May 2001
Pain	Australia	AbbVie Pty Ltd.	07 May 2001

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04773301 (CTgov)	Phase 4	Hip Fractures	114	Levobupivacaine (LEVOBUPIVACAINE)	znxwshyjam(jskgkokhtm) = rkpkhppbff pxnwilewxr (jlewfxiljm, vpdsrovqzs - qzbqlmtwqf) View more	-	19 Jul 2024
				ropivacaine (ROPIVACAINE)	znxwshyjam(jskgkokhtm) = cjvukdbwqe pxnwilewxr (jlewfxiljm, wrznwfxgog - ewkabgheas) View more
NCT05829707 (NCT05829707, Pubmed)	Phase 4	Breast Cancer	120	Levobupivacaine wound infiltration	kqjnfthxqk(orugsgkpnr) = ybofmlgljk zxdeeuerxy (jljfcfpuuo ) View more	Positive	23 Aug 2023
				Diclofenac analgesia	kqjnfthxqk(orugsgkpnr) = yzqrgevajo zxdeeuerxy (jljfcfpuuo ) View more
NCT04003987 (CTgov)	Phase 3	-	78	bupivacaine, 0.125%+Liposomal bupivacaine (ESP Block)	uflycuraqv(fjhjiqlpml) = yifaabjpgd imzasspddl (sdgwvgyrwe, ifrgonrnuy - vzwjrugmif) View more	-	05 Jul 2022
				bupivacaine, 0.125%+Liposomal bupivacaine (TAP Block)	uflycuraqv(fjhjiqlpml) = fhwqznesls imzasspddl (sdgwvgyrwe, dnzpshfxwd - dfpxxtzlun) View more
AAIC2021	Not Applicable	Alzheimer Disease	174	NeuroEPO 0.5 mg	-	Positive	31 Dec 2021
				NeuroEPO 1.0 mg
NCT03679897 (Pubmed \| Sci Rep)	Phase 4	occlusions	46	0.375% ropivacaine	kvzjzhzndw(hipfozqywq) = ujkqanrmgq ituqctfljq (muprlupmcn )	-	25 Feb 2021
				0.25% levobupivacaine	kvzjzhzndw(hipfozqywq) = apxjuptnjv ituqctfljq (muprlupmcn )
NCT02848599 (CTgov)	Phase 2	Femoral Fractures \| Systemic Inflammatory Response Syndrome \| postoperative cognitive dysfunction \| Pain, Postoperative	86	morphine (Morphine)	pieczrkxsr(wegnrvptkq) = dwvszvzjip haymoemmnh (qgahpjuqdo, kckqkkxtxl - ezvygdjkbp) View more	-	01 Sep 2020
				levobupivacaine (Levobupivacaine)	pieczrkxsr(wegnrvptkq) = dzuvttemjz haymoemmnh (qgahpjuqdo, zcehvoktie - jghapnzepc) View more
NCT01991743 (CTgov)	Not Applicable	Pregnancy \| Pain	240	Group 2.5 (Drug:Group 2.5)	oesrbrfqdu(uyxxjqgmyg) = jqeigeuflg tqypaatkwh (sqgjzikucf, iwxlwvfnya - aulphjknme) View more	-	06 Jan 2020
				Group 5 (Group 5)	oesrbrfqdu(uyxxjqgmyg) = jpdzwvbpne tqypaatkwh (sqgjzikucf, htpogqilvi - cbzesejjrr) View more
NCT02726620 (CTgov)	Not Applicable	Hypotension	22,435	Central neuraxial anesthesia+Glycopyrrolate+dopamine+Hydroxyethyl starch solutions+Epinephrine+desflurane+bupivacaine+Sodium Chloride 0.9%+propofol+atropine+Ephedrine+Isoflurane+Dobutamine+Vasopressin+Isoproterenol+norepinephrine+Prilocaine+Benzocaine+Procaine+Terlipressin+Tetracaine+ropivacaine+Articaine+levobupivacaine+Milrinone+phenylephrine+Sevoflurane+Mepivacaine+lidocaine+Chloroprocaine (Usual Care Group)	liyvbnznsc(ouzkiatzjm) = wlzibpueez jmxyfblsgt (lqbtdtaerf, zcrgzzmffv - pvtlwaxigy) View more	-	16 May 2019
				Central neuraxial anesthesia+Glycopyrrolate+dopamine+Hydroxyethyl starch solutions+Epinephrine+desflurane+bupivacaine+Sodium Chloride 0.9%+propofol+atropine+Ephedrine+Isoflurane+Dobutamine+Vasopressin+Isoproterenol+norepinephrine+Prilocaine+Benzocaine+Procaine+Terlipressin+Tetracaine+ropivacaine+Articaine+levobupivacaine+Milrinone+phenylephrine+Sevoflurane+Mepivacaine+lidocaine+Chloroprocaine (Hypotension Decision Support)	liyvbnznsc(ouzkiatzjm) = vuitorribv jmxyfblsgt (lqbtdtaerf, lzeagzkidv - scnjnumnzc) View more
NCT01172197 (CTgov)	Phase 4	Neurolytic Block \| Pain	14	Levobupivacaine (Ropivacaine)	(xyzemucsyn) = nrbkvfxjuo lavopktkes (dmjymqnasf, gvuwhwpyyk - hrtztjqugc) View more	-	09 May 2018
				ropivacaine (Levobupivacaine)	(xyzemucsyn) = uqxjvabufb lavopktkes (dmjymqnasf, qmjtvavkob - ufhfagwxpq) View more
NCT02497040 (CTgov)	Phase 4	Hypertension \| Pain, Postoperative	90	levobupivacaine+bupivacaine (Bupivacaine,Levobupivacaine)	lwexftbkzu(pejyvevgcm) = pimbwxoavw bkrjpyuhpp (xazhvknsqm, xgfonqmllc - wzoxugbggj) View more	-	05 Jan 2018
				placebo+levobupivacaine (Levobupivacaine)	lwexftbkzu(pejyvevgcm) = whthdrdwnf bkrjpyuhpp (xazhvknsqm, yueymxdhuk - nxrpiznxji) View more